Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
01 sept. 2022 16h15 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
16 août 2022 21h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
12 août 2022 07h00 HE
|
Iterum Therapeutics plc
--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq:...
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
11 juil. 2022 07h30 HE
|
Iterum Therapeutics plc
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022-- DUBLIN,...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2022 16h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 juin 2022 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports First Quarter 2022 Financial Results
13 mai 2022 07h00 HE
|
Iterum Therapeutics plc
-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) -- Iterum...
Iterum Therapeutics Provides Regulatory Update
11 mai 2022 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
25 avr. 2022 17h06 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
28 mars 2022 07h00 HE
|
Iterum Therapeutics plc
--Registration Trial for uUTI Planned in Second Half of 2022----Cash Runway into 2024-- --Company to host conference call today at 8:30am ET-- DUBLIN, Ireland and CHICAGO, March 28, 2022 (GLOBE...